Sohini Das &Amp; Samreen Ahmad

Stories by Sohini Das &Amp; Samreen Ahmad

COVID-19 vaccine: Why Poonawalla wrote to Biden

COVID-19 vaccine: Why Poonawalla wrote to Biden

Rediff.com   17 Apr 2021

'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'

100 million Covaxin vaccines by Sept

100 million Covaxin vaccines by Sept

Rediff.com   17 Apr 2021

The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.

Second Covid wave is 1.7x times faster than first wave, shows data

Second Covid wave is 1.7x times faster than first wave, shows data

Rediff.com   15 Apr 2021

It has taken 51 days to reach a daily caseload of 84,000 from 11,000, as against 85 days taken in the first wave, report Abhishek Waghmare and Sohini Das.

'We will be prioritising vaccine only for India'

'We will be prioritising vaccine only for India'

Rediff.com   14 Apr 2021

'I don't think anybody would want to be in my position today where every head of State has to be explained that I am prioritising my country because there is a surge in cases.'

Serum, Bharat Bio seek govt funds to boost vaccine output

Serum, Bharat Bio seek govt funds to boost vaccine output

Rediff.com   5 Apr 2021

Both manufacturers have sought funds in excess of Rs 150 crore under the department of biotechnology's Mission Covid Suraksha scheme. Announced last November, the scheme has an outlay of Rs 900 crore to help develop Covid vaccines, from the clinical development stage to setting up production sites.

Expert panel seeks more data on Sputnik V Covid vaccine

Expert panel seeks more data on Sputnik V Covid vaccine

Rediff.com   2 Apr 2021

'No approval was given to Sputnik V on Thursday. Some queries have been asked on safety, efficacy, and logistics, which the firm will have answers to at the next meeting'

Sputnik V vaccine may be added to India's Covid armoury soon

Sputnik V vaccine may be added to India's Covid armoury soon

Rediff.com   30 Mar 2021

'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).

Malabar Gold & Diamonds to invest Rs 1,600 cr on 56 stores

Malabar Gold & Diamonds to invest Rs 1,600 cr on 56 stores

Rediff.com   26 Mar 2021

Gold and diamond retail chain Malabar Gold & Diamonds will be investing Rs 1,600 crore in FY22 to launch 56 stores globally with 40 across India and 16 internationally in FY22 to further boost its retail presence across the globe. The move is expected to generate over 1,700 jobs. In India, the expansion strategy is centred in states like Tamil Nadu, Telangana, Andhra Pradesh, Karnataka, Maharashtra, Delhi, West Bengal, Uttar Pradesh, Odisha and Kerala. Internationally, the expansion will be in markets such as Singapore, Malaysia, Oman, Qatar, Bahrain and UAE.

As commodity prices rise, cars, home appliances to cost more

As commodity prices rise, cars, home appliances to cost more

Rediff.com   25 Mar 2021

Metal prices from copper to aluminum and tin have shot up by about 7-32 per cent in the past three months.

Bharat Biotech's Krishna Ella wins Covaxin fight

Bharat Biotech's Krishna Ella wins Covaxin fight

Rediff.com   22 Mar 2021

'He came back from the US only to work for his country.' 'He has invested his fortunes to build this company and is married to his work.' 'Rarely does one see such commitment.'

Koo is finally a true Indian company

Koo is finally a true Indian company

Rediff.com   18 Mar 2021

Koo has so far raised $4.1 mn in Series A funding from existing investors Accel, Kalaari Capital, Blume Ventures and 3one4 Capital.

How technology is changing fashion

How technology is changing fashion

Rediff.com   11 Mar 2021

From omnichannel to AI and 3D technology, the fashion industry is in the middle of a digital revolution.

Zostel claims win in 3-year legal battle against OYO, latter refutes

Zostel claims win in 3-year legal battle against OYO, latter refutes

Rediff.com   8 Mar 2021

Zostel could get upwards of $600 million if arbitration goes through.

Edtech, logistics and gig-economy to drive jobs

Edtech, logistics and gig-economy to drive jobs

Rediff.com   25 Feb 2021

Fresher hiring is expected to more than double compared to last year.

Public may get COVID-19 vaccine by April

Public may get COVID-19 vaccine by April

Rediff.com   22 Feb 2021

Anybody over 50 years of age or with co-morbidities can get a date, place and time of choice for getting the vaccine shots.

Low turnout forces govt to mull private rollout of Covid vaccine

Low turnout forces govt to mull private rollout of Covid vaccine

Rediff.com   10 Feb 2021

Two weeks after the vaccination programme started, about 37 per cent of the targeted 10 million healthcare professionals had received the first shot. This slow rate may prompt the government to allow vaccines in the private market sooner, to use up the doses before they expire, Sohini Das reports.

Lupin aims to enter Chinese market in the next one year

Lupin aims to enter Chinese market in the next one year

Rediff.com   8 Feb 2021

Once a difficult market to crack, in recent years, China has relatively opened up its drug market, enacting reforms and speeding up approval time.

More Covid vaccine candidates get approval for clinical trials in India

More Covid vaccine candidates get approval for clinical trials in India

Rediff.com   6 Feb 2021

Ahmedabad-based Zydus Cadila, Bharat Biotech's intra-nasal candidate are among the candidates who got approval from the expert panel to conduct clinical trials, Sohini Das reports.

More Indians will take vaccine if politicians do: Survey

More Indians will take vaccine if politicians do: Survey

Rediff.com   5 Feb 2021

In India, Opposition parties along with healthcare professionals have urged the government, including Prime Minister Narendra Modi and top leaders, to take either of the Covishield or Covaxin doses, which could help in drastically reducing trust and fear issues amongst citizens., reports Sohini Das.

Why early applicant Pfizer's Covid vaccine is delayed

Why early applicant Pfizer's Covid vaccine is delayed

Rediff.com   19 Jan 2021

Pfizer sought to participate in the Subject Expert Committee consultations towards an emergency use authorisation for its Covid-19 vaccine. However, the company representatives have been unable to participate in the meetings because of extremely short notices of a few hours or less and time-zone limitations.